Nonfactor therapies may reduce costs associated with bleeding-related hospitalizations and use of bypassing agents. One study in pediatric patients with inhibitors reported a decrease in the total ...
Geneventiv said the FDA had "positive" feedback in a meeting on developing GENV-HEM, the company's gene therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback